User:Monoclonalantibodies/Efavirenz

Efavirenz use should be avoided in patients that have experienced allergic reaction with past administration. Hypersensitivity reactions include Stevens–Johnson syndrome, toxic skin eruptions, and erythema multiforme.


 * edited only grammar, and moved from sandbox into the main article

Efavirenz is currently considered compatible in pregnancy. The safety of Efavirenz in pregnancy is still largely unknown. Current animal models suggested there is increased risk of neonatal neural tube defects during the first trimester of pregnancy. This has yet to be confirmed in human studies. Currently, the limited human studies available, do not show significant negative outcome associated with of continued use of Efavirenz throughout pregnancy. Additionally, the benefits of controlling viral transmission of HIV to offspring with the therapy out weight the potential neonatal risk seen in animal models. Efavirenz is contraindicated in breastfeeding. It has been confirmed in human studies that Efavirenz will pass into breast milk due to the low molecular weight of the drug therapy. Thus resulting in infant exposure to Efavirenz.


 * used briggs and the guideline original guideline
 * Restructured, citations added, hyperlinks added - moved into the live article

Efavirenz is considered compatible in pregnancy but the safety of the medication in humans is still largely unknown.

Neuropsychiatric effects are the most common adverse effects, and include disturbed sleep (including nightmares, insomnia, disrupted sleep, and daytime fatigue), dizziness, headache, vertigo, blurred vision, anxiety, cognitive impairment (including fatigue, confusion, and memory and concentration problems), and depression, including suicidal ideation. Some people may experience euphoria.
 * corrected information to match what is written below in the pregnancy and lactation section
 * moved from sandbox into the live article


 * change to some of the grammar in the sentence, only a few changes because did not want to alter the information. has been moved from the sandbox into the active article.